Epithelial ovarian cancer is the most lethal type of ovarian cancer, with a five-year survival rate of 18-46% upon diagnosis. But a new preclinical study has promising results: 83% of mice with ovarian cancer survived their diagnosis when they underwent nuclear medicine treatment that targeted the HER2 protein with anti-HER2 225Ac-PRIT. The group treated with traditional methods had only a 30% survival rate. This indicates promising results for targeted therapy in treating ovarian cancer. Check out this segment from NBC San Francisco to learn more: #nuclearmedicine #ovariancancer #cancer